Macrophage Colony-Stimulating Factor

A mononuclear phagocyte colony-stimulating factor (M-CSF) synthesized by mesenchymal cells. The compound stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series. M-CSF is a disulfide-bonded glycoprotein dimer with a MW of 70 kDa. It binds to a specific high affinity receptor (RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR).

Also Known As:

Networked: 1514 relevant articles (56 outcomes, 180 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Szmitkowski, Maciej: 25 articles (01/2015 - 04/2002)
2.	Stanley, E Richard: 21 articles (05/2013 - 01/2002)
3.	Mroczko, Barbara: 11 articles (10/2010 - 04/2002)
4.	Aharinejad, Seyedhossein: 10 articles (05/2012 - 09/2002)
5.	Athanasou, N A: 10 articles (03/2010 - 08/2000)
6.	Kelley, Vicki R: 9 articles (08/2015 - 03/2003)
7.	Ławicki, Sławomir: 9 articles (01/2015 - 06/2003)
8.	Czygier, Małgorzata: 9 articles (05/2010 - 06/2003)
9.	Jadus, Martin R: 9 articles (01/2009 - 01/2002)
10.	Abraham, Dietmar: 8 articles (03/2010 - 09/2002)

Related Diseases

1.	Infection 05/15/1991 - "When anti-HSV-2 activity of M-CSF was evaluated in guinea pigs by 6 daily injection (s.c.) of M-CSF at various doses (5 x 10(5) to 7 x 10(7) U/kg), we found 2 x 10(6) U/kg to be the optimum dose for protective efficacy against primary HSV-2 infection. " 06/01/1998 - "Animal models and clinical data suggest efficacy of M-CSF in controlling fungal infection." 04/01/2008 - "In addition, these studies demonstrate that M-CSF may have a role in the adaptive immune response to infection with M. " 09/01/1994 - "These studies demonstrating in vivo enhancement of anticryptococcal activity of macrophages with M-CSF provide a rationale for in vivo use of M-CSF to enhance resistance to infection with C. " 08/15/1991 - "Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections."
2.	Neoplasms (Cancer) 01/01/1989 - "However, when administered in vivo, CSF-1 increased the number of monocytes and peritoneal cells in tumor-bearing animals, and led to a significant reduction in the appearance of pulmonary and extra-pulmonary metastatic lesions derived from primary B16 tumors. " 03/01/1989 - "The M-CSF-treated cells were more effective in ADCC at lower effector to target cell ratios and in the presence of lower concentrations of tumor-specific monoclonal antibody than the untreated control cells. " 01/01/2013 - "We used 3 different mouse cancer models to study the effects of targeting cancer host myeloid cells with a monoclonal antibody (mAb) capable of blocking CSF-1 binding to murine CD115. " 03/15/2010 - "These studies demonstrated that increased CSF-1 production by host cells enhances TAM recruitment and NB growth and that the CSF-1 phenotype of NB tumor cells adversely affects survival." 10/01/2008 - "Recent experiments suggest that a tumor vaccine based on membrane-bound M-CSF-transduced tumor cells, combined with anti-angiogenic therapy, should be evaluated further for use in clinical trials."
3.	Neutropenia 07/20/2007 - "Finally, we illustrate use of these interval estimators with data simulated from a trial of using macrophage colony-stimulating factor to reduce febrile neutropenia incidence in acute myeloid leukaemia patients." 01/01/2013 - "We include an example studying the use of macrophage colony-stimulating factor to reduce the risk of febrile neutropenia events in acute myeloid leukaemia patients published elsewhere to illustrate the use of these estimators. " 11/01/2001 - "These findings indicate that severe impairment of granulocyte function leads to febrile neutropenia, and that M-CSF reduces the incidence of febrile neutropenia by maintaining or improving granulocyte function." 08/01/1997 - "Patients in the M-CSF group had 565 days and 133 episodes of febrile neutropenia during 7,901 days at risk, while patients in the placebo group had 977 days and 185 episodes during 9,077 days at risk. " 08/01/1997 - "The duration and incidence of febrile neutropenia was significantly reduced by 34% (P = .00285) and 17% (P = .02065), respectively, in 88 assessable patients in the M-CSF group compared with those in 94 assessable patients in the placebo group. "
4.	Inflammation 12/01/2014 - "Compared with the normal control group, positive reactions of pathological ankle joint section, inflammation, and osteoclasia degree were significantly improved in the model group, serum levels of RANKL and M-CSF were up-regulated, levels of OPG and OPG/RANKL were significantly lowered (all P < 0.01). " 12/10/2015 - "slan-defined subsets of CD16-positive monocytes: impact of granulomatous inflammation and M-CSF receptor mutation." 04/01/2015 - "Herein, we characterized the mechanisms underlying these changes as a platform to better understand the evolutionary origins of the CSF-1 immune-regulatory axis and inflammation control in teleosts. " 04/01/2013 - "Overall, our results provide new insights into ancient mechanisms of inflammation control and, in particular, the evolutionary origins of the CSF-1 immune regulatory axis." 01/01/2013 - "Both macrophage lineage branches are dependent on M-CSF during inflammation, and thus the potential for therapeutic interventions is marked. "
5.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/1991 - "Bone marrow and/or peripheral blood cells from seven patients with acute myelogenous leukemia (AML) were maintained for 7 weeks in Dexter-type long-term culture (LTC) in order to study the effect of exogenous recombinant human colony-stimulating factor-1 (rhCSF-1) and to quantitate endogenous levels of CSF-1. " 03/01/2012 - "The oncogenic potential of colony stimulating factor 1 receptor (CSF-1R) has been well described, while its relevance for human acute myelogenous leukemia (AML) is still undetermined. " 04/01/1997 - "Increased circulating colony-stimulating factor-1 (CSF-1) in SJL/J mice with radiation-induced acute myeloid leukemia (AML) is associated with autocrine regulation of AML cells by CSF-1." 11/01/1992 - "We have recently reported that normal long-term marrow cultures (LTMC) treated with recombinant human macrophage colony-stimulating factor (rhCSF-1), as well as LTMC from patients with acute myelogenous leukemia (AML), produce a soluble activity capable of inhibiting hemopoietic colony formation in semisolid cultures. " 10/01/1992 - "Composition and functional integrity of the in vitro hemopoietic microenvironment in acute myelogenous leukemia: effect of macrophage colony-stimulating factor."

Related Drugs and Biologics

1.	Macrophage Colony-Stimulating Factor
2.	Granulocyte Colony-Stimulating Factor (G-CSF)
3.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
4.	Cytokines
5.	Cytarabine (Cytosar-U)
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7.	Biological Tumor Markers (Tumor Markers)
8.	Interleukins
9.	Interferon-gamma (Interferon, gamma)
10.	Antigens

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
3.	East Asian Traditional Medicine (Oriental Medicine)
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Stem Cell Transplantation